Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Meta Platforms Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Meta Platforms Inc trades at $663.94 (market cap $1.70T). The key difference: Meta Platforms Inc is far larger — about 42.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Meta Platforms Inc pays a 0.31% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | META | |
|---|---|---|
Market Cap | $39.89B | $1.70T |
Sector | Health | Media |
52-Week High | $491.22 | $790.00 |
52-Week Low | $278.09 | $525.72 |
Enterprise Value | $38.15B | $1.70T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Meta Platforms (META) trades at $669.21, up 5.97% in the last 24 hours, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $201B and net income of $60.5B, maintaining high profitability margins. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $7.31 exceeding expectations of $6.70.
Outlook remains positive with analyst consensus price target of $820.94 representing 22.7% upside potential. Key risks include ongoing regulatory litigation and high capital expenditures for AI infrastructure. The stock trades at reasonable valuations with P/E of 24.33 and P/S of 7.99, supported by strong institutional ownership and 79% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
